Systematic Identification of Molecular Subtype-Selective Vulnerabilities in Non-Small-Cell Lung Cancer  by Kim, Hyun Seok et al.
Systematic Identification of Molecular
Subtype-Selective Vulnerabilities
in Non-Small-Cell Lung Cancer
Hyun Seok Kim,1 Saurabh Mendiratta,1 Jiyeon Kim,2 Chad Victor Pecot,5 Jill E. Larsen,3 Iryna Zubovych,4 Bo Yeun Seo,1
Jimi Kim,1 Banu Eskiocak,1 Hannah Chung,1 Elizabeth McMillan,1 Sherry Wu,5 Jef De Brabander,4 Kakajan Komurov,7
Jason E. Toombs,3 Shuguang Wei,4 Michael Peyton,3 Noelle Williams,4 Adi F. Gazdar,3 Bruce A. Posner,4
Rolf A. Brekken,3 Anil K. Sood,6 Ralph J. Deberardinis,2 Michael G. Roth,4,8 John D. Minna,3,8 and Michael A. White1,8,*
1Department of Cell Biology
2Children’s Medical Center Research Institute
3Hamon Center for Therapeutic Oncology Research
4Department of Biochemistry
University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
5Division of Cancer Medicine
6Center for RNA interference and Non-Coding RNA
University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
7Division of Biomedical Informatics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA
8These authors contributed equally to this work
*Correspondence: michael.white@utsouthwestern.edu
http://dx.doi.org/10.1016/j.cell.2013.09.041SUMMARY
Context-specific molecular vulnerabilities that arise
during tumor evolution represent an attractive inter-
vention target class. However, the frequency and
diversity of somatic lesions detected among lung
tumors can confound efforts to identify these targets.
To confront this challenge, we have applied parallel
screening of chemical and genetic perturbations
within a panel of molecularly annotated NSCLC lines
to identify intervention opportunities tightly linked to
molecular response indicators predictive of target
sensitivity. Anchoring this analysis on a matched
tumor/normal cellmodel froma lungadenocarcinoma
patient identified three distinct target/response-indi-
cator pairings that are represented with significant
frequencies (6%–16%) in the patient population.
These include NLRP3 mutation/inflammasome
activation-dependent FLIP addiction, co-occurring
KRAS and LKB1 mutation-driven COPI addiction,
and selective sensitivity to a synthetic indolotriazine
that is specified by a seven-gene expression signa-
ture. Target efficacies were validated in vivo, and
mechanism-of-action studies informed generalizable
principles underpinning cancer cell biology.INTRODUCTION
Widespread evidence indicates that aberrant cancer cell-regula-
tory frameworks generate collateral vulnerabilities that can be552 Cell 155, 552–566, October 24, 2013 ª2013 Elsevier Inc.exploited for therapeutic benefit. These vulnerabilities can be a
consequence of oncogene addiction, gene-specific haploinsuf-
ficiencies, and other genetically and epigenetically derived fragil-
ities in cell-regulatory systems (Ja¨nne et al., 2009; Luo et al.,
2009; Muller et al., 2012). The critical barrier confronting this
opportunity, for many tumor types, is the extreme heterogeneity
of themolecular etiology of neoplastic disease, which confounds
annotation of effective context-selective intervention targets.
For non-small-cell lung cancer (NSCLC), a tumor responsible
for 1 million deaths/year, over 160 nonsynomous somatic muta-
tions are detected per tumor, and the vast majority of these
mutations are nonrecurrent (Cancer Genome Atlas Research
Network, 2012; Imielinski et al., 2012). Actionable mutations
have been identified in epidermal growth factor receptor
(EGFR) and EML4-ALK (Lynch et al., 2004; Soda et al., 2007)
but are present in only 15% of lung adenocarcinomas (Imielinski
et al., 2012), whereas the majority of NSCLC patients are not
associated with any known pharmaceutically addressable
target. This missing coverage underscores the need to develop
new target opportunities that are tightly linked to molecular
response indicators.
To generate a testbed representative of the molecular hetero-
geneity of NSCLC, we assembled a panel of 91 lung tumor-
derived cell lines and 3 immortalized nontumorigenic airway
epithelial cultures. Though limited by the sparse complexity of
the tissue culture environment and therefore limited in the syn-
thetic genetic and chemical interactions that can be observed,
this cell-line panel has been shown to recapitulate genetic pro-
files found in tumors and to recapitulate selective responsive-
ness to molecularly targeted therapies (Gazdar et al., 2010;
Sharma et al., 2010). Beginning with a matched tumor/normal
cell model from a single lung adenocarcinoma patient, 230,000
synthetic small molecules and two independent whole-genome
arrayed small interfering RNA (siRNA) libraries were used to iden-
tify chemical and genetic perturbations selectively toxic to the
patient’s tumor cell line. These agents were then tested to iden-
tify perturbations that were innocuous to nontumorigenic cells
but had activity in at least 30% of the NSCLC cell lines. The re-
sulting toxicity patterns were correlated with genomic profiles
to identify somatic mutations and expression signatures that
predicted sensitivity or resistance to these perturbations. In
this way, we identified three distinct target/response-indicator
pairings. First, we found that NLRP3 mutations, which occur in
16% of lung adenocarcinomas, drive addiction to the antiapop-
totic protein FLIP. The mechanism of action is through NLRP3-
dependent chronic activation of inflammasome signaling, which
sensitizes these cells to FLIP-dependent restraint of caspase-8-
induced cell death. Second, we found that co-occurring muta-
tions in KRAS and LKB1, present in 6% of lung adenocarcinoma
patients, are sufficient to drive addiction to the coatomer com-
plex I (COPI)-dependent lysosome acidification. This liability
was determined to be a consequence of obligate supply of
TCA-cycle substrates by lysosome-dependent consumption of
extracellular macromolecules. Chemical inhibition of this pro-
cess, with the natural product saliphenylhalamide A, inhibited
KRASmut/LKB1mut tumor cell survival in vitro and in vivo. Finally,
we found that selective sensitivity to a synthetic indolotriazine
defines a subtype of NSCLC cells estimated to occur at a fre-
quency of 10% of lung tumors. Indolotriazine sensitivity corre-
sponded to selective activation of an endoplasmic reticulum
stress response and can be effectively predicted using a
seven-gene quantitative mRNA expression signature.
RESULTS
Public and Private Vulnerabilities in NSCLC
To begin to assess the diversity of selective vulnerabilities that
can arise within lung cancer cell-autonomous regulatory con-
texts, we selected a matched tumor/normal pair (HCC4017/
HBEC30KT), derived from a 62-year-old female smoker with
stage 1A adenocarcinoma, for extensive functional and genomic
interrogation (Figure 1A). Authentic somatic mutations and copy
number variation, in the tumor line as compared to normal
cells, were identified from whole-exome hybridization-capture
sequencing (1303 average read-depth; Table S1 and Data S1
available online). Two hundred and ninety-six nonsynonymous
exonic single-nucleotide somatic variants were detected in
HCC4017 (Figure 1B), 152 of which are predicted to be delete-
rious to protein function (Data S1). Copy number variation was
extensive, as estimated by exon read-depth (Figures 1B and
S1A) and SNP array (Figure S1A), and correlated with relative
mRNA concentrations as determined by RNA sequencing
(RNA-seq) (Data S2; Figure S1A). Two whole-genome arrayed
siRNA libraries and a collection of 230,000 chemical com-
pounds were then screened to identify agents selectively toxic
to HCC4017 versus HBEC30KT (Data S2 and S3).
A Z score cutoff of 3 was used to identify candidate
HCC4017-selective siRNA sensitivities. This thresholding re-
sulted in predominantly nonoverlapping sets of candidates
from each siRNA library, presumably due to a combination of
false-negative and false-positive relationships. As previouslydescribed (Jacob et al., 2011), the former is at least partially an
artifact of assigned selection thresholds. In direct support of
this, the empirical cumulative distribution of the Z scores from
siRNA pools in library 1, corresponding to ‘‘hits’’ from library 2,
indicated a significant enrichment of activity as compared to
the background distribution (Figure S1B). To defend against
false positives, individual oligos were tested for each of the
326 nonredundant hits from the union of the two libraries
together with a K-S statistic that predicts oligonucleotide seed
sequence-specific activity that is independent of target deple-
tion (Tables S2 and S3; Data S4). Eighty-five surviving siRNA
pools that were reproduced in HCC4017 and also innocuous
upon testing in HBEC30KT and two additional telomerase/
CDK4-immortalized nontumorigenic HBEC lines were then
examined across a panel of 21 additional NSCLC cell lines
(Data S5; Figures 1C and S1C).
A striking feature of the response of the cell-line panel to the
siRNA collection was the largely idiosyncratic activity pattern
(Figure 1C). Forty percent of the tested siRNAs had measurable
consequences on the viability of 10% or less of the cell-line
panel, and no single siRNA pool was identified with activity in
over 90% of the panel (Data S5; Figure 1C). Manual curation of
the biological processes served by the siRNA target genes
indicated an enrichment of signal transduction machinery and
transcription factors within the ‘‘private’’ target class and an
enrichment of housekeeping machines (cell-cycle control,
mRNA splicing, ribosomal proteins, and vesicle trafficking) within
the ‘‘public’’ target class (Data S6; Figure 1D). Among the private
targets, small-molecule inhibition of USP8 (Gue´dat and Colland,
2007) largely recapitulated the selectivity of siRNA-mediated
USP8 depletion, suggesting bona fide selectivity (Figure S1D).
We found significant correlation of the private target class of
HCC4017-sensitive siRNAs with low-target gene expression,
suggesting that the private nature of some targets may be at
least partially a consequence of expression bias (Figure S1E).
As a whole, siRNA targets were recovered evenly from all
genomic loci with the exception of homozygously deleted re-
gions where, as expected, none were located (Figures 1B and
S1F). However, a slightly larger number of hits (CACNA2D4,
POM121L12, TMEM106B, BZW2, RBBP9, HBA1, NUPL2,
SDK1, VSTM2A, C16orf54, and CYC1) were identified from
amplified and overexpressed loci as compared to the rest of
the genome (Figures S1F and S1G). A first-degree interaction
network was constructed to identify potential coherent relation-
ships among HCC4017-selective targets and the somatic muta-
tions detected within that cell line (Figure S1H). Though verifiable
and informative relationships were detected (Figures S1I and
S1J), direct connections to somatic variation appear insufficient
to account for the high frequency of private vulnerabilities iden-
tified within this cell line.
Context-Selective FLIP Addiction
We prioritized relationships found in at least 30% of the NSCLC
panel to afford an opportunity for codetection of genetic
response indicators. Depletion of CFLAR, which encodes the
catalytically inactive caspase-8 analog FLIP (Irmler et al., 1997),
was sufficient to markedly induce apoptosis in HCC4017 cells
and was toxic to multiple additional NSCLC lines as comparedCell 155, 552–566, October 24, 2013 ª2013 Elsevier Inc. 553
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Figure 1. Public and Private Genetic Vulnerabilities
(A) Schematic of discovery platform for target/biomarker relationships.
(B) Genome-wide view of relative genomic DNA content, mRNA content, and RNAi toxicity in HCC4017 by two independent siRNA libraries (orange
indicates Z < 3).
(C) Penetrance of the HCC4017 RNAi hits in 22 NSCLC lines.
(D) Gene ontology (%) of the private (n = 30; response in 1–2 lines) and public (n = 48; response in > 2 lines) RNAi hits. Subgraphs from the PPI network (see
Figure S1H) are displayed in the boxes.
See also Figure S1, Tables S1, S2, and S3, and Data S1, S2, S4, S5, and S6.to nontumorigenicbronchial epithelial cells (DataS5;FigureS1C).
Cell lines from the two tails of the toxicity profile, derived from
testing CFLAR depletion in 22 NSCLC lines, were selected for
interrogation of molecular features correlating with sensitivity to
CFLAR depletion (Figure 2A). From whole-genome mRNA
expression profiles, PYCARD, IFIT2, and IFIT3 were identified
as the top-ranked genes commonly upregulated in CFLAR-
dependent versus CFLAR-independent cell lines (Figure 2A,
bottom panel). This expression model was sufficient to predict
additional CFLAR-dependent cell lines from an unsupervised
hierarchical cluster of a panel of 34 lines outside the original dis-554 Cell 155, 552–566, October 24, 2013 ª2013 Elsevier Inc.covery set (Figure S2A). FLIP restrains execution of programmed
cell death pathways through direct suppression of caspase-8
(Tschopp et al., 1998). FLIP addiction, therefore, infers the pres-
ence of latent death signals that are released upon removal of
prosurvival restraints. This scenario is akin to the selective sensi-
tivity of cancer cells to chemical mimics of SMAC (second mito-
chondria-derived activator of caspase) in the presence of tumor
necrosis factor (TNF)-dependent apoptotic signaling, which is
the consequence of uncoupling inhibitor of apoptosis proteins
(IAPs) from otherwise active caspases (Tenev et al., 2011). How-
ever, only two of seven FLIP-dependent cell lines examinedwere
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Figure 2. Context-Selective FLIP Addiction
(A) Bar plots indicate toxicity of CFLAR depletion in the most sensitive (relative viability < 0.3) and most resistant NSCLC cell lines (> 0.9) and two nontumorigenic
lines. Heatmap indicates the gene-expression signature with the maximal bimodal distribution between groups. SMAC mimetic responsiveness is indicated as
determined by LD50 (Table S5). Error bars indicate ± standard deviation (SD, n = 3).
(B) The indicated siRNAs were tested for consequences on siCFLAR-dependent toxicity within each of the CFLAR-dependent cell lines. Error bars as in (A).
(C) The indicated siRNAs were tested for consequences on SMAC mimetic-induced toxicity within each of the SMAC mimetic-responsive cell lines. Error
bars as in (A).
(D) Pfam-A domain structure of NALP3 and maps of somatic mutations found.
(E) Empirical CDF plot of PYCARD expression from lung adenocarcinomas with or without highly deleterious mutations in NLRP3 (TCGA).
(F) Consequence of NLRP3 depletion on CFLAR dependency; **p < 0.01, *p < 0.05 by two-sided unpaired Student’s t test. siRNA-mediated NLRP3 gene
depletion is indicated as measured by quantitative PCR (qPCR) (right). Error bars as in (A).
(G) Tumor weights (g) following treatment with either control or CFLAR siRNAs. Error bars indicate ± standard error of the mean (SEM). *p = 0.026 by Wilcoxon
rank sum test.
See also Figure S2 and Table S4.
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additionally sensitive to SMAC-mimetic exposure, suggesting
that FLIP can restrain programmed cell-death signals indepen-
dently of SMAC-responsive IAPs (Figure 2A; Table S4). FLIP
dependence did not correlate with expression of FLIP, its pro-
death partner caspase-8, or SMAC-mimetic-resistant IAP2 (Pe-
tersen et al., 2010) (Figure S2B). However, sensitivity to FLIP
depletion was completely reversed upon caspase-8 codepletion
(Figure 2B). In contrast, SMAC-mimetic sensitivity was minimally
affected by caspase-8 depletion and completely reversed by
depletion of RIP1 kinase, an initiator of ripoptosome assembly
that is negatively regulated by IAPs (Feoktistova et al., 2011;
Tenev et al., 2011) (Figure 2C). Rescue of FLIP addiction by
depletion of individual core components of the ripoptosome, or
other canonical-death-pathway activators implicated in cancer,
was cell line selective (Figure 2B). This suggests multiple distinct
regulatory contexts within the NSCLC panel converge on FLIP-
dependent restraint of caspase-8-initiated cell death. By its
nature, the PYCARD, IFIT1, IFIT2 expression signature is serving
as a common indicator of these distinct contexts (Figure 2A).
IFIT1 and 2 are primary response genes induced by interferon
and may ordinarily mediate cytotoxic responses to pathogen
detection (Wathelet et al., 1988). PYCARD encodes ASC, a
component of the inflammasome whose expression is also
responsive to inflammasome activation signals (Masumoto
et al., 2006; Strowig et al., 2012). Of note, HCC4017 harbors a
somatic nonsense mutation in the inflammasome component
NLRP3 located in the linker region between the N-terminal
NACHT domain andC-terminal leucine-rich repeat (LRR) domain
(p.Y591*, Figure 2D). This alteration is predicted to encode a trun-
cated, constitutively active protein, due to loss of LRR-domain-
mediated repression of the NACHT domain (Hu et al., 2013).
Derepression of NACHT domains promotes promiscuous NALP
oligomerization and interaction with CARD domain proteins like
ASC (Strowig et al., 2012). Somatic exonic NLRP3 mutations
are present in 16% of lung adenocarcinomas (Figure S2C, 21/
129 in the LUAD TCGA samples) (Cerami et al., 2012), and
NLRP3 mutant adenocarcinomas were significantly enriched
for NF-kBactivity (FigureS2D), suggesting thatNLRP3mutations
in this context may be gain-of-function alterations. In support of
this, highly deleterious mutations in NLRP3 are significantly
associated with PYCARD overexpression within the TCGA
adenocarcinoma data set (Figure 2E), and there is an overall sig-
nificant positive correlation between PYCARD and NLRP3
expression (Figure S2E). Targeted sequencing revealed an anal-
ogous nonsensemutation in the FLIP-dependent cell line HCC15
(p.E401*) and a missense mutation in the FLIP-dependent cell
line HCC366 (p.S727Y) (Barretina et al., 2012). Importantly, like
caspase-8, codepletion of NLRP3 relieved sensitivity of NSCLC
lines to FLIP depletion, suggesting that NLRP3 activity helps
drive FLIP addiction (Figure 2F). Furthermore, NLRP3 mutation
status was significantly associated with sensitivity to FLIP deple-
tion (Figure S2F), and two additionalNLRP3mutantNSCLC lines,
identified fromoutside of the original tested panel, were also FLIP
dependent (Figure S2G).
To model conservation of FLIP addiction within a tumorigenic
context, we assessed the effects of CFLAR knockdown in a
mouse xenograft model. Two weeks following subcutaneous in-
jection of HCC15 cells, mice were randomly divided and treated556 Cell 155, 552–566, October 24, 2013 ª2013 Elsevier Inc.with siRNAs incorporated into DOPC nanoliposomes (intraperi-
toneal [i.p.] administration) according to the following treatment
groups (n = 10/group): control siRNA/DOPC and CFLAR
siRNA/DOPC for 4 weeks. In comparison to the control siRNA
group, tumors from theCFLAR siRNA group had a 87.2% reduc-
tion in tumor mass (p = 0.026; Figure 2G). These cumulative
observations indicate that FLIP may represent an intervention
opportunity in lung cancer linked to enrollment biomarkers that
include NLRP3 mutation status.
KRAS/LKB1 Mutation Status Specifies Coatomer 1
Addiction
Next, the mutation statuses for five recurrently mutated genes
(TP53, CDKN2A, KRAS, STK11 [LKB1], NRAS), collected by tar-
geted sequencing, were queried for association with each of 85
siRNA toxicity profiles (Table S1; Data S5). Of note, co-occur-
rence of KRAS/LKB1 mutations was significantly associated
with sensitivity to depletion of COPI subunits ARCN1, COPB1,
and COPA (Figure S3A). Approximately 6% of lung adenocarci-
noma patients have co-occurring KRAS/LKB1 mutations (Imie-
linski et al., 2012). COPI participates in retrograde transport, is
required for endosome maturation (Huotari and Helenius,
2011; Razi et al., 2009), and is a CDC42 effector required for
CDC42 transformation (Wu et al., 2000). From the intersection
of the first-degree interaction network of HCC4017-essential
genes (Figure S1H) and the commonality of responsiveness
with the larger NSCLC cell-line panel (Figures 1C and 1D), we
identified a total of five of seven components of the COPI.
NSCLC cell lines representing the two tails of the distribution
of sensitivity to COPI subunit depletion are shown in Figure 3A.
Inhibition of COPI expression in multiple telomerase-immortal-
ized bronchial epithelial cells was relatively innocuous and
comparable to the consequence of COPI depletion in the
COPI-resistant cancer lines (Figures 3A and 3B). Sensitivity to
COPI depletion was recapitulated in soft-agar colony formation
assays (Figure 3C). To assess the therapeutic utility of targeting
the COPI subunit ARCN1, we utilized an orthotopic lung adeno-
carcinoma model capable of spontaneous metastasis. One
week after surgical introduction of A549 cells into the left lung,
mice were randomly divided and treated with siRNAs incorpo-
rated into DOPC nanoliposomes (i.p. administration) according
to the following treatment groups (n = 10/group): control siRNA
or ARCN1 siRNA for 5 weeks. Treatment with ARCN1 siRNAs
led to substantial reductions in primary tumor size (92.9% by
volume, p = 0.0087; 51.3% by left lung mass, p = 0.0032) as
well as metastastic burden (90.4% reduction, p = 0.0015) (Fig-
ures 3D and S3B). This sensitivity correlated with hypophos-
phorylation of Rb and induction of cell-cycle arrest and
apoptosis in vitro (Figures S3C and S3D). HCC4017 was an
outlier with respect to LKB1 mutation status; however, this line
has a defective AMPK response and therefore is the functional
equivalent of COPI-addicted cell lines with compound lesions
in KRAS and LKB1 (Figure 3E). Importantly, co-occurrence of
KRAS and LKB1 mutations was a robust predictor of COPI
addiction when tested in NSCLC cell lines outside the original
discovery panel (Figure 3F), and LKB1 depletion was sufficient
to sensitize KRAS mutant/LKB1 wild-type cell lines to COPI
depletion (Figure 3G).
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Figure 3. KRASmut/LKB1mut Mutation Status Specifies Coatomer 1 Addiction
(A) RNAi toxicity profiles of themost sensitive andmost resistant NSCLC lines to siRNA pools targeting COPI are shown.Mutation statuses of theKRAS and LKB1
are indicated: M (mutant) or WT (wild-type).
(B) The indicated cell lines were transfected with the indicated siRNAs in 96-well plates and incubated for 48 hr followed by transfer to 24-well plates and in-
cubation for an additional 6 days. Crystal violet-stained wells are shown. The immunoblot indicates persistence of target depletion in HBEC3 at the 8 day
time point.
(C) The consequence of COPI depletion on HCC4017 colony formation in soft agar is shown. Error bars indicate ± SD, n = 3.
(D) Therapeutic effects of ARCN1 siRNA in an orthotopic lung adenocarcinoma model (A549). Mets: metastasis. Error bars indicate ± SEM. One-sided Wilcoxon
rank sum test p values were all < 0.01 (**).
(E) Consequence of AICAR on AMPK activation in two COPI-dependent (HCC4017 and H460) and two independent (H2009 and H441) KRAS mutant lines.
(F) Additional NSCLC lines from outside the test panel, with known KRASmut/LKB1mut status, were assayed for BrdU incorporation to detect consequences of
COPI depletion on proliferation as shown. Error bars as in (C).
(G) Consequence of LKB1/COPI codepletion in KRAS mutant cells. Immunoblots indicate target depletion. Error bars as in (C).
See also Figure S3.
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Figure 4. Oncogenic KRAS together with LKB1 Loss Is Sufficient to Induce COPI Addiction
(A) Steady-state accumulation of the indicated proteins and phospho-proteins was assessed by immunoblot of whole-cell lysates from the indicated HBEC30KT
derivatives.
(B) Representative hematoxylin and eosin staining (H&E) images of xenograft tumors formed upon subcutaneous inoculation of HBEC30KT-shTP53/KRASG12V/
shLKB1, indicating mixed adenosquamous (top) and squamous (bottom) histology.
(C) Toxicity profile of the HCC4017 siRNA hits within the HBEC30KT progression series. The 17/85 siRNAs selectively toxic to the KRASmut/LKB1mut cell lines are
shown.
(D) Viability distributions of siRNA pools from 4C across 18 NSCLC lines with the indicated genotypes. Box plot whiskers extend to ± 1.5 interquartile range (IQR).
Two-sided K-S test p values for all pair comparisons against the double mutants are less than 1010 (**).
(E) The indicated cells were stained with crystal violet as in Figure 3B. Immunoblot indicates persistence of target depletion in resistant cells at the 8 day
time point.
See also Figure S4.Oncogenic KRAS together with LKB1 Loss Is Sufficient
to Induce COPI Addiction
To evaluate the sufficiency of compound KRAS and LKB1
perturbation for induction of COPI addiction, we engineered a
series of HBEC30KT derivatives with stepwise stable suppres-
sion of p53, stable expression of KRASG12V, and stable suppres-
sion of LKB1 (Figures 4A, S4A, and S4B). Among these, only the
final derivative was tumorigenic in immune-compromised mice,
and tumors presented with mixed adeno/squamous characteris-
tics (Figure 4B). This mixed morphology is strikingly similar to
that observed in spontaneous mouse lung tumors that arise as
a consequence of KrasG12V expression in an Lkb1 null back-
ground (Ji et al., 2007). A screen of 85 siRNA pools correspond-
ing to the HCC4017-essential genes, within the HBEC30KT
isogenic progression series, revealed acquired vulnerability to558 Cell 155, 552–566, October 24, 2013 ª2013 Elsevier Inc.17 targets within the KRASmut/LKB1mut background (Figure 4C).
Sensitivity to depletion of these same 17 genes was significantly
enriched in KRASmut/LKB1mut NSCLC cell lines as compared to
that in other NSCLC lines tested (Figure 4D). COPI subunits were
present in this context, indicating that KRASmut/LKB1mut status
is sufficient to specify COPI addiction (Figure 4E).
The KRASmut/LKB1mut NSCLC Subtype Mirrors the
Mesenchymal (Claudin-Low) Subtype of Triple-Negative
Breast Cancer
Gene set enrichment analysis (GSEA) of whole-genome tran-
script profiles from COPI-sensitive versus COPI-resistant cell
lines returned EMT, NF-kB, and tryptophan metabolism as
significantly associated with KRASmut/LKB1mut status (Table
S5; Figure S5A; nominal p < 0.01), though none of these
signatures cleanly segregated the two classes. An siCOPI
toxicity-associated gene-expression signature, with bimodal
distribution, returned a more focused separation centered on
chemokines and cytokines (Figure S5B, FDR < 0.001) reminis-
cent of the oncogenic RAS-induced secretory senescence
phenotype (Coppe´ et al., 2008). Remarkably, 30% of the top
100 most differentially expressed genes, as defined by signal-
to-noise ratio, intersected the molecular classification signature
for the mesenchymal, or ‘‘claudin-low,’’ subtype of triple-nega-
tive breast cancer (Prat et al., 2010) (Figure 5A, hypergeometric
p < 6.7 3 1016). Consistent with this, we found that three
‘‘claudin-low’’ breast cancer cell lines (Prat et al., 2010) were
sensitive to COPI depletion as compared to cell lines corre-
sponding to the lumenal A or basal A subtypes (Figure 5B). The
mesenchymal subtype of triple-negative breast cancer is an
aggressive metastatic disease enriched with self-renewing
tumor-initiating cells (Prat et al., 2010). Dichotomization of 272
molecularly and clinically annotated lung tumor samples, using
the expression signature defined by COPI addiction, revealed
significantly reduced overall survival and disease-free survival
for patients harboring signature-positive tumors (Figures 5C
and S5C). Importantly, this relationship was reproducible with
an independent patient cohort and data set (Figure S5D).
To parse molecular correlates that may provoke COPI addic-
tion, we employed a focused suppressor screen that queried
genes and pathways enriched in the COPI-sensitive cell lines
(Figures S5E and S5F; see Experimental Procedures for ratio-
nale). The most significant interaction recovered was inter-
leukin-6 (IL-6) pathway activation (Figure S5E). IL-6 secretion
was significantly elevated in the COPI-sensitive lung and breast
cancer cell lines, including the HBEC30KT progression series
(Figures S5G, S5H, and S5I). Oncogenic RAS expression was
sufficient to induce IL-6 production; however, co-occurring
loss of LKB1 signaling enhanced this phenotype in human
epithelial cells and in mouse tumors (Figures S5I, S5J, and
S5K). Inhibition of IL-6 signaling by IL-6 depletion, IL-6R deple-
tion, or Let-7 expression significantly suppressed COPI addic-
tion (Figures 5D, 5E, 5F, and S5L).
IL-6 has been characterized as a RAS-responsive cytokine
that promotes tumorigenesis in a paracrine fashion by provoking
stromal remodeling of the tumormicroenvironment (Coppe´ et al.,
2008). Consistent with this, we found that IL-6 secretion was
KRAS dependent in COPI-addicted cell lines (Figure 5G).
Furthermore, the tryptophan metabolism expression signature
associated with COPI-addicted (KRASmut/LKB1mut) cell lines
(Figure S5A) implicated aryl hydrocarbon receptor (AhR)
signaling as amechanism thatmay contribute to IL-6 production.
AhR induces IL-6 production in metastatic glioma, and both
kynurenine and kynurenic acid, produced during tryptophan
synthesis, serve as endogenous AhR ligands (Opitz et al.,
2011). Consistent with this, depletion of AhR or the AhR nuclear
translocator (ARNTL) significantly reduced IL-6 secretion (Fig-
ure 5H). Taken together, these observations suggest that selec-
tion for IL-6 secretion within the tumor microenvironment has
collateral consequences on tumor cell biology that provoke
addiction to COPI function. COPI activity thus becomes a collat-
eral vulnerability that, if targetable, may represent a precision
intervention opportunity.Lysosomal Maturation Is Required to Support
Mitochondrial Oxidative Phosphorylation and Survival of
KRASmut/LKB1mut NSCLC Cells In Vitro and In Vivo
LKB1/AMPK-dependent repression of acetyl-CoA carboxylases
(ACC1/2) can deflect catastrophic accumulation of oncogenic
RAS-induced reactive oxygen species in cultured cells. This is
thought to occur by limiting consumption of NADPH by ACC
for fatty-acid synthesis, which in turn increases the NADPH/
NADP+ ratio needed to maintain the cellular redox state (Jeon
et al., 2012; Son et al., 2013). This presents a compelling mech-
anistic scenario whereby KRASmut/LKB1mut cells are selectively
sensitized to perturbations that impair reduction of reactive oxy-
gen. In contradiction to this expectation, we found that gluta-
thione or N-acetyl cysteine failed to rescue COPI addiction and
were instead individually toxic (Figure S5F). Furthermore, the
free radical scavenger NDGA displayed synthetic toxicity to
KRASmut/LKB1mut expression in the HBEC30KT background,
consistent with the reported prosurvival role of reactive oxygen
within the context of oncogenic RAS expression (Figure S6A)
(Irani et al., 1997).
To help uncover the mechanistic basis of COPI addiction, we
assembled a panel of chemical probes that (1) intersect biolog-
ical processes coupled to COPI function, (2) inhibit signaling
pathways dysregulated in the KRASmut/LKB1mut background,
or (3) engage cell-stress responses predicted to be induced by
COPI depletion. The dose-dependent toxicity response to these
compounds was then measured across 20 cell lines. Within this
panel, the vacuolar ATPase inhibitor bafilomycin A1 (bafA) was
discovered to have significant selective toxicity against the
KRASmut/LKB1mut cell lines (Figure 6A) independent of ROS
(Figures S6B and S6C). Like COPI depletion, exposure to
50 nM bafA for 48 hr induced CDKI accumulation, Rb hypophos-
phorylation, and caspase activation (Figure S6D). This suggests
that KRASmut/LKB1mut cells may be selectively dependent upon
lysosomal maturation, which is itself dependent upon COPI
complex activity (Huotari and Helenius, 2011; Razi et al., 2009).
A comparison of steady-state organelle accumulation revealed
dramatic enrichment of acidic lysosomes in KRASmut/LKB1mut
cells as compared to COPI-insensitive cells (Figure S6E).
Furthermore, gain of COPI dependency through LKB1 depletion
in a KRAS mutant NSCLC line, H2009, was coupled to the accu-
mulation of the lysosomal membrane protein LAMP2 (Fig-
ure S6F). The elevated lysosomal activity in KRASmut/LKB1mut
cells was reversed upon COPI subunit depletion independently
of detectable morphological perturbation of the Golgi (Figures
6B and S6G) and by bafA concentrations below those required
to inhibit lysosomal acidification of non-KRASmut/LKB1mut
NSCLC cells (Figure S6H). A gene-expression feature (top-
ranked GO term by GSEA) associated with COPI dependency
and KRASmut/LKB1mut status was the enrichment of energy deri-
vation by oxidation (Table S5; Figure S6I). Related to this, we
noted that COPI depletion, exposure to bafA, or exposure to a
structurally distinct vATPase inhibitor, saliphenylhalamide A
(saliPhe) (Lebreton et al., 2008), resulted in the concomitant
appearance of dysmorphic mitochondria in KRASmut/LKB1mut
cells (Figures 6B and 6C) but not in bafA-resistant cells (Fig-
ure S6J). This altered morphology corresponded to reduced ox-
ygen-consumption rates together with increased extracellularCell 155, 552–566, October 24, 2013 ª2013 Elsevier Inc. 559
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Figure 5. The KRASmut/LKB1mut NSCLC Subtype Mirrors the Mesenchymal (Claudin-Low) Subtype of Triple-Negative Breast Cancer
(A) Top 100 differentially regulated genes as identified by signal-to-noise ratio between COPI-dependent and -independent cancer lines. Claudin-low signature
genes are indicated in red for upregulated (10/437) and blue (19/370) for downregulated genes, hypergeometric p < 6.7 3 1016.
(B) Selective consequence of ARCN1 depletion on the viability of breast cancer cell lines. Error bars indicate ± SD, n = 3.
(C) Patient cohorts with the COPI-addicted gene-expression signature (Cluster I) show poor prognosis. Kaplan-Meier plots are shown for overall (left) and cancer-
free survival (right) of the patient populations dichotomized as described in Figure S5C. p values are log-rank test.
(legend continued on next page)
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acidification rates, suggesting impaired oxidative phosphoryla-
tion and concomitant induction of glycolysis (Figures 6D and
S6K). However, this mitochondrial dysfunction was not coupled
to loss of mitochondrial membrane potential (Figure S6L).
Rather, bafA and saliPhe inhibited incorporation of heavy car-
bons from 13C-labeled glucose or glutamine into citrate, consis-
tent with inhibition of the mitochondrial TCA cycle (Figure 6E).
Perhaps through a futile adaptive response, loss of TCA-cycle
activity was paralleled by increased glucose and glutamine con-
sumption concomitant with conversion to secreted lactate and
glutamate (Figures S6M and S6N). This phenotype was also
observed in response to COPI depletion (Figure S6O). Finally,
we found that direct inhibition of vATPase assembly by
ATP6V1B2 depletion was sufficient to prevent lysosomal acidifi-
cation (Figure 6F) and inhibit mitochondrial respiration (Fig-
ure 6G). These observations indicate that lysosomal maturation
is selectively required to support mitochondrial function in
KRASmut/LKB1mut cells. The coupling of this vulnerability to a
genetic background that promotes energetic stress led us to
consider the possibility that KRASmut/LKB1mut cells are selec-
tively dependent upon hydrolysis of lysosomal macromolecules
for supply of mitochondrial TCA-cycle substrates. We found that
delivery of cell-permeable pyruvate (methyl pyruvate, MP) or
a-ketoglutarate (dimethyl-2-oxoglutarate, MOG), two major car-
bon sources fueling the mitochondrial TCA cycle, rescued cell
viability and mitochondrial respiration in the presence of bafA
(Figures 6H and S6P). Importantly, this rescue occurred without
restoration of lysosomal acidification (Figure S6Q), consistent
with the hypothesis that lysosomes support mitochondrial func-
tion through supply of an obligate nutrient source in KRASmut/
LKB1mut cells. Perdurant acetyl-CoA carboxylase activity in the
KRASmut/LKB1mut background is likely a mechanism that helps
drive lysosomal addiction, as ACC1 depletion rescued cell
viability in the presence of bafA (Figure 6I). We suspect that
ACC1 inactivation is facilitating productive fatty-acid beta-
oxidation as an alternate energy source due to depletion of
malonyl-coA, an ACC1 product that inhibitsmitochondrial import
of long-chain fatty acids (Abu-Elheiga et al., 2001). These obser-
vations present a compelling argument for consideration of lyso-
somes as a metabolic bottleneck by which to target energy
homeostasis in KRASmut/LKB1mut lung cancer cells. To model
this in vivo, mice bearing established HCC4017 subcutaneous
xenografts were exposed to saliPhe (12.5 mg/kg/day, n = 5) or
vehicle (n = 4) using osmotic pumps implanted i.p. The pumps
eluted drugs for 17 days, at which time tumors in the vehicle-
treated group were 174% larger, whereas tumors in the
saliPhe-treated animals were 40% of the starting volume. The
effect of saliPhe was durable as tumors were allowed to grow
for an additional 35 days in the absence of further drug exposure,
and tumors in saliPhe-treated animals were 4-fold smaller than
tumors in vehicle-treated animals (0.116 ± 0.27 g versus 0.46 ±
0.13 g; p < 0.05) (Figure 6J).(D–F) Consequences of codepletion of IL6 (D) and IL6R (E) or exposure to Let-7 f
bars as in (B).
(G and H) IL-6 secretion was measured by ELISA post-transfection of the indica
**p < 0.01, *p < 0.05, two-sided unpaired Student’s t test; error bars as in (B).
See also Figure S5 and Table S5.A Gene-Expression Model Predicts Sensitivity to a
Synthetic Compound, Indolotriazine
To collect additional chemical probes for detection of subtype-
selective vulnerabilities inNSCLC,we examined 352 compounds
(out of 230,000 screened) that were selectively toxic to HCC4017
cells versusHBEC30KTat 2.5 mM(Figure S7A;DataS3-1 andS3-
2). Two of the 352 compounds displayed bimodal LD50s across
12 NSCLC lines (>3-fold separation of ‘‘sensitive’’ versus ‘‘resis-
tant’’ lines). Among these, an indolotriazine, SW044248, was
selectively toxic in 18/74 NSCLC lines and innocuous up to the
highest testable dose in four different telomerase-immortalized
bronchial epithelial cell lines (Figure 7A; Data S3-3). To inform
the mode of action, resistant HCC4017 subclones were isolated
following long-term exposure to the compound. RNA-seq identi-
fied differential gene-expression responses to SW044248, in
parental versus resistant HCC4017 variants, corresponding to
a strong and selective ER stress-response signature (Figure 7B;
Data S7) (Hetz, 2012). Consistent with this, CHOP and IRE1a
were robustly induced within 24 hr of exposure to SW044248
(Figure 7C). This response was uniform among the SW044248-
sensitive NSCLC lines but absent in resistant lines (Figure 7D).
The latter is most likely a consequence of selective vulnerability
rather than selective exposure as equivalent SW044248 accu-
mulation and stability were observed in both sensitive and resis-
tant cell lines as detected by gas chromatography-mass spec-
trometry (GC-MS) (Figures S7B and S7C).
To identify features that may predispose to the indolotriazine
sensitivity, we searched for gene-expression networks that corre-
lated with the compound responsiveness within the cell-line
panel. Two ER stress-related networks were ranked among the
top discoverable networks by edge flux (EF) and process flux
(PF) values (Figure S7D) (Komurov et al., 2012). In addition, an
elastic net regression model using basal gene-expression
data identified seven genes (C8G, PSG7, ACOT6, DEPDC5,
MMP16, UBR1, and CYP4F22) as robust indicators of indolotria-
zine responsiveness (Figures 7E and S7E). Feature performance
was filtered by a 2003 bootstrapping protocol, fromwhich all fea-
tures were detected at frequencies > 50%. The sum of the
weighted features in this model were used to predict SW044248
sensitivity from a panel of 38 NSCLC lines outside of the training
set. HCC2429 and H1770 represented the two tails (sensitive
and resistant) of the distribution of predicted IC50s, which were
empirically validated with eight-point dose-response curves (Fig-
ure 7F). Twenty-three of 231 lung adenocarcinomas were within
the left-hand tail of the frequency distribution of elastic net scores,
suggesting that 10% of tumors contain expression features
consistent with SW044248 sensitivity (Figure S7F).
DISCUSSION
Widespread evidence indicates that acquired vulnerabilities,
arising in the course of tumor evolution, represent keyamily of miRNA mimics (F) on siRNA toxicity of indicated COPI subunits. Error
ted siRNAs in the indicated cell lines. Values were normalized to cell number.
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therapeutic intervention opportunities. Starting from within the
context of a single lung adenocarcinoma patient, we identified
genetic and chemical vulnerabilities selectively associated with
tumorigenicity. However, the incidence of these vulnerabilities,
within a lineage-restricted panel of NSCLC-derived cell lines,
was highly idiosyncratic. By focusing on perturbations with sig-
nificant activity in a large cell-line panel, we could begin to detect
intervention targets linked to molecular subtypes that specify
target sensitivity and have reasonable frequencies of represen-
tation within the lung cancer patient population.
A robust, but previously unrecognized, genotype/phenotype
relationship uncovered by this approach is the selective addic-
tion of NLRP3 mutant cells to FLIP. FLIP is widely recognized
as a candidate oncology target opportunity due to its role in
deflection of caspase-8-dependent programmed cell death
(Safa and Pollok, 2011), but distinct genetic settings that specify
FLIP dependence had not been elaborated. NLRP3 triggers
inflammasome assembly and consequent activation of NF-kB
and cytokine production upon detection of microbial infection
or cellular injury (Bryant and Fitzgerald, 2009; Manji et al.,
2002). It is constitutively expressed in epithelial cells but, in the
absence of ‘‘danger signals,’’ is thought to exist in an autoinhi-
bited state (Hu et al., 2013). Of note, mutations in NLRP3 result
in persistent cytokine production and are the causal lesions for
CAPS, a group of congenital autoinflammatory diseases (Hoff-
man et al., 2001). In light of NLRP3’s role in innate immune
signaling, it is reasonable to suspect that the frequent NLRP3
alterations found in lung tumors could contribute to tumor
growth by inflammatory signal-mediated recruitment of stromal
cell populations. In this scenario, positive selection for NLRP3
variants that stimulate production of a protumorigenic niche cre-
ates a collateral dependence on FLIP inhibition of apoptosis. The
mechanistic coupling may be direct given recent observations
that the NLRP3 inflammasome can bind and activate caspase-8
(Gringhuis et al., 2012; Pierini et al., 2012; Sagulenko et al., 2013).
Direct chemical inhibition of FLIP is not currently available; how-
ever, a variety of small molecules that inhibit FLIP expression orFigure 6. Lysosomal Maturation Is Required to Support Mitochondrial
Cells In Vitro and In Vivo
(A) Compound mimic screen. The indicated compounds were tested over 11 dose
versus HBEC30KT and others (n = 14). Area under the curve (AUC) was estimated
were performed to discriminate compounds with selective activity. K-S test p va
(B) HCC44 cells, transfected with the indicated siRNAs were stained with the
Lysotracker negative versus 3.0% of siNC cells; p value < 2.2 x 1016; Fisher’s e
(C) Confocal imaging of mitochondrial morphology after 42 hr exposure to vATPas
had dysmorphic mitochondria versus 2.7% with DMSO; p value < 2.2 x 1016 fo
(D) Oxygen consumption rates (OCR) of HCC44 cells exposed to the indicated c
(E) Mass isotopomer analysis of citrate in HCC44 cells cultured with D[U-13C]glu
unlabeled glucose (right for each cell line) after exposure to 10 nM BafA or 1 mM
(F) Live-cell images obtained as in (B) and (C).
(G) As in (D), except that HCC44 cells were transfected with the indicated siRNAs
mitochondria versus 0% of siNC cells; p value < 2.2 x 1016; Fisher’s exact test;
(H) Caspase-3 and -7 activity was measured after exposure of HCC4017 to DMS
oxoglutarate (MOG, 5 mM), or water (CTL). Error bars as in (B).
(I) Indicated siRNAs were tested for consequences on bafA (10 nM) dependent to
Error bars as in (B).
(J) 2.5 3 106 HCC4017 cells were injected subcutaneously into NOD/SCID mice.
with saliPhe or saline as indicated.
Error bars indicate ± SEM. See also Figure S6 and Table S5.enhance FLIP degradation have been reported (Safa and Pollok,
2011; Zhao et al., 2011) and may represent a path forward for
pharmacological targeting of NLRP3 mutant lung cancers.
Detection of oncogenic KRAS-linked vulnerabilities is a high-
priority, but often confounding, pursuit in multiple neoplastic
settings because of the frequency of representation of this onco-
gene in human tumors.Within the context of NSCLC cells, loss of
LKB1 activity together with expression of oncogenic KRAS is
required and sufficient to drive COPI addiction. This genetic
interaction reinforces the notion that all KRAS cancers are not
equivalent, and robust mapping of intervention opportunities
must account for distinct collaborative alterations that result in
distinct collateral vulnerabilities. COPI participates in a variety
of dynamic membrane-trafficking events and is well studied for
its role in support of retrograde transport (Lee et al., 2004).
However, we found that the mechanistic basis of COPI addiction
in the KRASmut/LKB1mut background is the obligate contribution
of this protein complex to lysosome acidification. Chemical or
genetic perturbation of lysosome maturation in KRASmut/
LKB1mut cells resulted in mitochondrial malfunction and cell
death. Mitochondrial dependence on lysosomal maturation
was bypassed by supply of cell-permeable TCA-cycle sub-
strates, including pyruvate and a-ketoglutarate. This, together
with the observation thatKRASmut/LKB1mut cells displayed signs
of elevated lysosomal flux, strongly suggests that this molecular
subtype requires consumption and hydrolysis of extracellular
macromolecules for minimal supply of cellular metabolic inter-
mediates. Recognition of lysosomal function as a context-
dependent metabolic bottleneck is reinforced by three additional
recent observations. First, the coupling of lysosome acidification
capacity to mitochondrial health has been defined as a key
determinant of cellular aging in yeast (Hughes and Gottschling,
2012). Second, pancreas cancer cells mount an adaptive
response to glutamine starvation by induction ofmacropinocyto-
sis and consequent consumption of extracellular macromole-
cules as an amino-acid supply route (Commisso et al., 2013).
Third, dysregulation of mTORC1 drives addiction toOxidative Phosphorylation and Survival of KRASmut/LKB1mut NSCLC
s (23 serial dilution) for toxicity in HCC4017 and KRASmut/LKB1mut lines (n = 6)
by the sum of % viability over testing doses. One-sided two-sample K-S tests
lues in negative log scale were used to generate the plot.
indicated dyes and antibodies. Seventy-one percent of siARCN1 cells were
xact test.
e inhibitors. Ninety-two percent of bafA-treated and 85% saliPhe-treated cells
r both; Fisher’s exact test.
ompounds. Error bars indicate ± SD, n = 3.
cose and unlabeled glutamine (left for each cell line) or L[U-13C]glutamine and
saliPhe for 16 hr. **p < 0.01, *p < 0.05, two-sided t test, error bars as in (B).
prior to the assay. Ninety-three percent of siATP6V1B2 cells had dysmorphic
error bars as in (B).
O or bafA (5 nM) for 48 hr together with methyl pyruvate (8 mM), dimethyl-2-
xicity in HCC44 and A549. Cells were exposed to bafA 48 hr post-transfection.
Tumor volume versus days post-tumor injection is displayed for mice treated
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Figure 7. A Gene-Expression Model Predicts Sensitivity to an Indolotriazine
(A) AC50 for the HCC4017-selective synthetic indolotriazine derivative against 74 additional NSCLC cell lines and immortalized HBECs.
(B) Top 10 differential gene-expression responses to SW044248 (2 mM, 6 hr) in HCC4017 parental (P) and resistant clones (RS, RW) as detected by RNA-seq
(ANOVA, p < 0.005, Data S7).
(C) Relative accumulation of CHOP, IRE1a, and BiP proteins upon exposure of HCC4017 for the indicated times.
(D) As in (C) except with a 24 hr exposure with indicated cell lines.
(E) Predictive basal gene-expression features for SW044248 sensitivity in 48 NSCLCs by elastic net regression modeling. Compound response (AC50) is indi-
cated in the top row. Predictive gene-expression features (normalized by samplemedian) across 48 NSCLCs are shown. Bar plot on the left indicates the average
weight for the corresponding feature as determined from a 2003 bootstrapping analysis. Frequency of feature occurrence is shown in parenthesis.
(F) Dose-response curves for a predicted sensitive cell line, HCC2429, and a predicted resistant cell line, H1770, based on the expression signature-derived
scoring function. Error bars indicate ± SD, n = 3.
See also Figure S7 and Data S3-1, S3-2, S3-3, and S7.consumption of exogenous desaturated lipids to support endo-
membrane expansion (Young et al., 2013). The incidence of co-
occurring KRAS and LKB1 mutations in NSCLC is estimated to
be 6% of all lung adenocarcinomas, which corresponds to
5,000 new cancer patients per year in the USA alone. Establish-564 Cell 155, 552–566, October 24, 2013 ª2013 Elsevier Inc.ing KRASmut/LKB1mut mutation status as a robust indicator of
COPI addiction presents the opportunity to exploit clinical labo-
ratory-based detection of somatic alterations in these genes as
an enrollment biomarker to stratify patient populations predicted
to respond to chemical perturbation of lysosome maturation.
Screening of a large diversity-based collection of synthetic
small molecules revealed a chemical liability in cancer cell lines
that share distinct gene-expression features. Although the target
of this compound remains to be defined, the mode-of-action
appears to be through selective mobilization of the unfolded pro-
tein response and consequent cell death. Of interest, a relatively
large but highly selective cohort is responsive to the indolotria-
zine SW044248 (24% of cell lines tested). Thus, SW044248
can be described as a chemical discriminator of a distinct
NSCLC subtype. If indolotriazine sensitivity is preserved in the
in vivo setting, this chemical discriminator becomes a lead for
therapeutically relevant pharmacological characterization of
discrete vulnerabilities within this subtype.
In summary, cell-based exploration of lung cancer intervention
opportunities can be a rich source of target discovery given suf-
ficient commonality of sensitivity and resolution of molecular
correlates. Starting with disease-cell-selective vulnerabilities
present in isolates from a single lung cancer patient, two distinct
molecular targets were identified, linked to two distinct genetic
lesions, which together are represented in over 25% of lung
adenocarcinoma patients. In addition, a chemically defined
vulnerability was identified that is associated with an expres-
sion-based biomarker estimated to occur in 10% of lung cancer
patients.
EXPERIMENTAL PROCEDURES
Materials, procedures, and computational analysis including deep sequenc-
ing, high-throughput screening, and associated data processing and analysis;
mouse xenograft studies, mitochondrial respiratory potential, metabolic flux,
pharmacokinetic analysis, and elastic net regression modeling; and other
statistical processing protocols are detailed in the Extended Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, five tables, and seven data sets and can be found with this article
online at http://dx.doi.org/10.1016/j.cell.2013.09.041.
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